PubRank

Jennifer A Westwood

Author PubWeight™ 34.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006 7.09
2 Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013 2.07
3 Activation of NK cell cytotoxicity. Mol Immunol 2005 2.03
4 Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002 1.96
5 Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002 1.92
6 Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002 1.50
7 Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 2005 1.40
8 Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013 1.33
9 Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013 1.29
10 Autoimmunity associated with immunotherapy of cancer. Blood 2011 1.22
11 Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res 2007 1.19
12 Gene modification strategies to induce tumor immunity. Immunity 2005 1.12
13 Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res 2007 1.06
14 Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 2011 1.05
15 Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res 2010 1.04
16 Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2013 0.98
17 Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother 2011 0.95
18 Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 2007 0.94
19 Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci U S A 2009 0.94
20 Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 2002 0.87
21 Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 2008 0.86
22 Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLoS One 2013 0.84
23 Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment. J Cancer Surviv 2015 0.84
24 Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor. Immunotherapy 2013 0.77
25 Erratum to: Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment. J Cancer Surviv 2015 0.75